Navigation Links
Rosetta Genomics Reports First Quarter 2008 Financial Results
Date:5/21/2008

Rosetta Genomics' technology in 2008, and Rosetta's expected cash usage in 2008 constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the continued uncertainty in the credit and capital markets that may result in these markets deteriorating further or Rosetta experiencing additional ratings downgrades on any ongoing investments in its portfolio (including on ARS); changes in the accounting treatment and final results for 2007 resulting from final third party valuations of the ARS; the current lack of liquidity of the ARS having a impact on Rosetta's liquidity, cash flow or its ability to fund its operations; other changes in general economic and business conditions; Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products or services; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products and services; the successful development of diagnostic and therapeutic products applying Rosetta's technology, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals for products, as may be required under applicable laws; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta'
'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
(Date:7/30/2014)... 30, 2014 Selexis SA , ... drug discovery and mammalian cell line development, announced today ... ™ will be presented at the 10th Annual ... September 8 – 10, 2014 at the Double Tree ... The following abstract will be presented during an oral ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... will support Phase 3 Trials for Crohn,s Disease, Pouchitis and ... ... 20 Ocera Therapeutics, a,biopharmaceutical company focused on the licensing, ... of,gastrointestinal and liver diseases, has announced the completion of a,$35.5 ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today ... Pharmaceuticals GmbH (Merz) for sales,by Merz and its ... Alzheimer,s disease for the quarter ended September 30,2007. ... royalty payments on sales of Memantine by Merz ...
... Rensselaer Polytechnic Institute have demonstrated that liquids embedded ... exposed to electric fields. The finding could lead ... phone displays, and other microscale fluidic devices. , ... for using nanofluids in microscale and nanoscale actuator ...
Cached Biology Technology:Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine 2Strengthening fluids with nanoparticles 2
(Date:7/31/2014)... State University researchers have completed a 20-year study ... Hills prairie at different times of the year. ... late spring time frame has no measurable negative ... have multiple benefits. , The study was conducted ... Prairie Biological Station fire chief, and Joseph Craine, ...
(Date:7/31/2014)... scientists from Spain, France, and the U.S. has ... the oldest definitive member of the tribe Omaliini ... discovery and description were made possible through the ... technique, which allows the detailed study of otherwise ... is described in the journal Annals of ...
(Date:7/31/2014)... German . ... to a sponge that soaks up liquids. Hence, these ... greenhouse gases. However, loading of many MOFs is inhibited ... now report in Nature Communications that the ... This can be prevented by water-free synthesis and storing ...
Breaking Biology News(10 mins):Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3Free pores for molecule transport 2
... 22, 2010) The National Science Foundation has awarded ... Biological Laboratory $1.7 million to repair and rebuild its ... the pier has played an instrumental role in the ... change, fisheries management and the health of the Chesapeake ...
... reporting the development and successful initial testing of a new ... to be given as nose drops rather than injected. It ... they say. The report appears in ACS, Molecular Pharmaceutics ... note that brain cancer is difficult to treat, partly because ...
... water," which resembles powdered sugar, could provide a new ... greenhouse gas that contributes to global warming, scientists reported ... Society. The powder shows bright promise for a number ... be a greener, more energy-efficient way of jump-starting the ...
Cached Biology News:UMCES Chesapeake Biological Laboratory to rebuild historic research pier 2
... Immunogen: Recombinant human IDO (Indoleamine-pyrrol ... the ~44 kDa human IDO ... control: IFN-Gamma-stimmulated Human peripheral blood ... reactivity with mouse and rat ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
... total protein western blot (WtPAN) ... tissue specific protein expression in ... protein is included in each ... for comparison between different western ...
Biology Products: